Statin use was found to be associated with delayed disease progression and reduced mortality in prostate cancer. Despite the mechanism by which statins possibly preventing cancer progression not yet being completely understood, the beneficial effects associated with statins and their relatively safe profile make them good candidates for additional therapy to standard treatment for prostate cancer.

A retrospective cohort study was conducted using the Taiwan Cancer Registry of 2008~2014. This study included 5749 men with locally advanced and metastatic PC who received only androgen deprivation therapy (ADT) in the first year after their cancer diagnosis. In this population study with 3.6 years of follow-up on average, patients showed a substantial decrease in mortality associated with statin use in men with metastatic disease following ADT. This is one of the largest patient populations with advanced PC following ADT, and results indicated the potential of statins as a therapy for men with non-metastatic high-risk and hormone-sensitive metastatic PC. Results also showed marked differences among individual statins, which provides important evidence for selecting the most appropriate statin for secondary prevention trials. Patients who received atorvastatin, pravastatin, rosuvastatin, or pitavastatin showed a stronger reduction in mortality than those who received other statins. This study focused on men with advanced prostate cancer patients with solely ADT treatment because that this is the group of patients who will gain the most benefit from adjuvant treatment if statins do decrease their all cause and prostate cancer mortality. While the 10-year survival among men with early stage prostate cancer is more than 90%, the benefit gained from statin in men with early stage prostate cancer is very small. This piece of evidence provides important information on the most appropriate target patient population and the types of statins for clinical trials to confirm the effects of statins in improving outcomes among men with prostate cancer.

Written by: Szu-Yuan Wu, Su-Chen Fang, Hung-Jen Shih, Yu-Chin Wen and Yu-Hsuan Joni Shao

Read the Abstract